Identification

Name
Gatifloxacin
Accession Number
DB01044  (APRD00996)
Type
Small Molecule
Groups
Approved, Investigational
Description

Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin® for the treatment of respiratory tract infections, having licensed the medication from Kyorin Pharmaceutical Company of Japan. Allergan produces an eye-drop formulation called Zymar®. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. [Wikipedia]

Structure
Thumb
Synonyms
  • 1-Cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
  • 1-cyclopropyl-6-fluoro- 8-methoxy-7-(3-methylpiperazin-1-yl)- 4-oxo-quinoline-3-carboxylic acid
  • Gatifloxacin anhydrous
  • Gatifloxacine
  • Gatifloxacino
  • Gatifloxacinum
Product Ingredients
IngredientUNIICASInChI Key
Gatifloxacin sesquihydrateL4618BD7KJ180200-66-2RMJMZKDEVNTXHE-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GatifloxacinSolution / drops5 mg/mLOphthalmicPacific Pharma2015-04-15Not applicableUs
TequinTablet200 mgOralBristol Myers Squibb2004-01-162006-06-29Canada
TequinTablet400 mgOralBristol Myers Squibb2001-02-212006-06-29Canada
Tequin IVLiquid10 mgIntravenousBristol Myers Squibb2001-03-142006-06-29Canada
Tequin IVSolution2 mgIntravenousBristol Myers Squibb2002-01-052006-06-29Canada
ZymarSolution0.3 %OphthalmicAllergan2004-09-27Not applicableCanada
ZymaxidSolution / drops5 mg/mLOphthalmicPhysicians Total Care, Inc.2011-08-31Not applicableUs
ZymaxidSolution / drops5 mg/mLOphthalmicAllergan2010-05-19Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-gatifloxacinSolution0.3 %OphthalmicApotex CorporationNot applicableNot applicableCanada
GatifloxacinSolution / drops5 mg/mLOphthalmicHi Tech Pharmacal Co., Inc.2014-10-06Not applicableUs
GatifloxacinSolution / drops5 mg/mLOphthalmicSandoz2016-10-03Not applicableUs
GatifloxacinSolution / drops5 mg/mLOphthalmicLupin Pharmaceuticals2013-10-01Not applicableUs
GatifloxacinSolution / drops5 mg/mLOphthalmicLupin Pharmaceuticals2013-10-01Not applicableUs
Categories
UNII
81485Y3A9A
CAS number
112811-59-3
Weight
Average: 375.3941
Monoisotopic: 375.159434412
Chemical Formula
C19H22FN3O4
InChI Key
XUBOMFCQGDBHNK-UHFFFAOYSA-N
InChI
InChI=1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26)
IUPAC Name
1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
SMILES
COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1

Pharmacology

Indication

For the treatment of bronchitis, sinusitis, community-acquired pneumonia, and skin infections (abscesses, wounds) caused by S. pneumoniae, H. influenzae, S. aureus, M. pneumoniae, C. pneumoniae, L. pneumophila, S. pyogenes

Structured Indications
Pharmacodynamics

Gatifloxacin is a synthetic broad-spectrum 8-methoxyfluoroquinolone antibacterial agent for oral or intravenous administration. is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Gatifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. It should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Mechanism of action

The bactericidal action of Gatifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.

TargetActionsOrganism
ADNA gyrase subunit A
inhibitor
Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)
ADNA gyrase subunit B
inhibitor
Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)
ADNA topoisomerase 4 subunit A
inhibitor
Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)
ADNA topoisomerase 4 subunit B
inhibitor
Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)
Absorption

Well absorbed from the gastrointestinal tract after oral administration with absolute bioavailability of gatifloxacin is 96%

Volume of distribution
Not Available
Protein binding

20%

Metabolism

Gatifloxacin undergoes limited biotransformation in humans with less than 1% of the dose excreted in the urine as ethylenediamine and methylethylenediamine metabolites

Route of elimination
Not Available
Half life

7-14 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Enteric bacteria and other eubacteria
  • Mycobacterium
  • Chlamydia pneumoniae
  • Chlamydia trachomatis
  • Mycoplasma pneumoniae
  • Legionella pneumophila
  • Chlamydia psittaci
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Gatifloxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Gatifloxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Gatifloxacin.Experimental, Illicit
AcarboseGatifloxacin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
AcemetacinAcemetacin may increase the neuroexcitatory activities of Gatifloxacin.Approved
AcenocoumarolGatifloxacin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Gatifloxacin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Gatifloxacin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Gatifloxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Gatifloxacin.Approved
AlbiglutideGatifloxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclofenacAlclofenac may increase the neuroexcitatory activities of Gatifloxacin.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Gatifloxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Gatifloxacin.Experimental, Investigational
AlgeldrateAlgeldrate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmagateAlmagate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlmasilateAlmasilate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlminoprofenAlminoprofen may increase the neuroexcitatory activities of Gatifloxacin.Experimental
AlogliptinGatifloxacin may increase the hypoglycemic activities of Alogliptin.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AluminiumAluminium can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Gatifloxacin.Experimental, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Gatifloxacin.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Gatifloxacin.Approved
AndrographolideAndrographolide may increase the neuroexcitatory activities of Gatifloxacin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Gatifloxacin.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Gatifloxacin.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Gatifloxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Gatifloxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Gatifloxacin.Approved
ApocyninApocynin may increase the neuroexcitatory activities of Gatifloxacin.Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Gatifloxacin.Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Gatifloxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Gatifloxacin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Gatifloxacin.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Gatifloxacin.Approved, Investigational
BendazacBendazac may increase the neuroexcitatory activities of Gatifloxacin.Experimental
BenorilateBenorilate may increase the neuroexcitatory activities of Gatifloxacin.Experimental
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Gatifloxacin.Withdrawn
BenzydamineBenzydamine may increase the neuroexcitatory activities of Gatifloxacin.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Gatifloxacin.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Gatifloxacin.Approved, Investigational
BevoniumBevonium may increase the neuroexcitatory activities of Gatifloxacin.Experimental
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BromfenacBromfenac may increase the neuroexcitatory activities of Gatifloxacin.Approved
BromocriptineGatifloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the neuroexcitatory activities of Gatifloxacin.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Gatifloxacin.Approved
BufexamacBufexamac may increase the neuroexcitatory activities of Gatifloxacin.Experimental
BumadizoneBumadizone may increase the neuroexcitatory activities of Gatifloxacin.Experimental
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gatifloxacin.Approved
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CitrateCalcium Citrate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Calcium lactateCalcium lactate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium laevulateCalcium laevulate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium pangamateCalcium pangamate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium PhosphateCalcium Phosphate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanagliflozinGatifloxacin may increase the hypoglycemic activities of Canagliflozin.Approved
Carbaspirin calciumCarbaspirin calcium may increase the neuroexcitatory activities of Gatifloxacin.Experimental, Investigational
CarprofenCarprofen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Vet Approved, Withdrawn
CaseinCasein can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CastanospermineCastanospermine may increase the neuroexcitatory activities of Gatifloxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
ChloroquineChloroquine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Vet Approved
ChlorpropamideGatifloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the neuroexcitatory activities of Gatifloxacin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Gatifloxacin.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Gatifloxacin.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Gatifloxacin.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Gatifloxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Gatifloxacin.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Gatifloxacin.Approved
ClorindioneGatifloxacin may increase the anticoagulant activities of Clorindione.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Gatifloxacin.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Gatifloxacin.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Gatifloxacin.Approved
CurcuminCurcumin may increase the neuroexcitatory activities of Gatifloxacin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Gatifloxacin.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Gatifloxacin.Experimental
D-LimoneneD-Limonene may increase the neuroexcitatory activities of Gatifloxacin.Investigational
DapagliflozinGatifloxacin may increase the hypoglycemic activities of Dapagliflozin.Approved
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Gatifloxacin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Gatifloxacin.Approved
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Gatifloxacin.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Gatifloxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Gatifloxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Gatifloxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Gatifloxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Gatifloxacin.Vet Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Gatifloxacin.Approved, Vet Approved
DicoumarolGatifloxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Gatifloxacin.Approved
DifenpiramideDifenpiramide may increase the neuroexcitatory activities of Gatifloxacin.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Gatifloxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Gatifloxacin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Gatifloxacin.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Gatifloxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Gatifloxacin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Gatifloxacin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Gatifloxacin.Approved
DiphenadioneGatifloxacin may increase the anticoagulant activities of Diphenadione.Experimental
DisopyramideGatifloxacin may increase the hypoglycemic activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gatifloxacin.Approved, Investigational
DroxicamDroxicam may increase the neuroexcitatory activities of Gatifloxacin.Approved
DulaglutideGatifloxacin may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibDuvelisib may increase the neuroexcitatory activities of Gatifloxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Gatifloxacin.Approved
E-6201E-6201 may increase the neuroexcitatory activities of Gatifloxacin.Investigational
EmpagliflozinGatifloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EpirizoleEpirizole may increase the neuroexcitatory activities of Gatifloxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Gatifloxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Gatifloxacin.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Gatifloxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Gatifloxacin.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
EthenzamideEthenzamide may increase the neuroexcitatory activities of Gatifloxacin.Experimental
Ethyl biscoumacetateGatifloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
ExenatideGatifloxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindexisulind may increase the neuroexcitatory activities of Gatifloxacin.Investigational
FelbinacFelbinac may increase the neuroexcitatory activities of Gatifloxacin.Experimental
FenbufenFenbufen may increase the neuroexcitatory activities of Gatifloxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Gatifloxacin.Approved
FentiazacFentiazac may increase the neuroexcitatory activities of Gatifloxacin.Experimental
FeprazoneFeprazone may increase the neuroexcitatory activities of Gatifloxacin.Experimental
Ferric CarboxymaltoseThe serum concentration of Gatifloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric CitrateThe serum concentration of Gatifloxacin can be decreased when it is combined with Ferric Citrate.Approved, Investigational
Ferric pyrophosphateThe serum concentration of Gatifloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
Ferulic acidFerulic acid may increase the neuroexcitatory activities of Gatifloxacin.Experimental
FloctafenineFloctafenine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Gatifloxacin.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Gatifloxacin.Approved
FluindioneGatifloxacin may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Gatifloxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Gatifloxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Gatifloxacin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the neuroexcitatory activities of Gatifloxacin.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Gatifloxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Gatifloxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Gatifloxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Gatifloxacin.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Gatifloxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Gatifloxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Gatifloxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Gatifloxacin.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Gatifloxacin.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Gatifloxacin.Approved, Investigational, Withdrawn
GitoformateGitoformate may decrease the cardiotoxic activities of Gatifloxacin.Experimental
GliclazideGatifloxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideGatifloxacin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideGatifloxacin may increase the hypoglycemic activities of Glipizide.Approved
GlyburideGatifloxacin may increase the hypoglycemic activities of Glyburide.Approved
GuacetisalGuacetisal may increase the neuroexcitatory activities of Gatifloxacin.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Gatifloxacin.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Gatifloxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Gatifloxacin.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gatifloxacin.Approved, Vet Approved
HydrotalciteHydrotalcite can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
IbuprofenIbuprofen may increase the neuroexcitatory activities of Gatifloxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Gatifloxacin.Withdrawn
IcatibantIcatibant may increase the neuroexcitatory activities of Gatifloxacin.Approved
Imidazole salicylateImidazole salicylate may increase the neuroexcitatory activities of Gatifloxacin.Experimental
IndobufenIndobufen may increase the neuroexcitatory activities of Gatifloxacin.Investigational
IndomethacinIndomethacin may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Gatifloxacin.Withdrawn
Insulin AspartGatifloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirGatifloxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineGatifloxacin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineGatifloxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanGatifloxacin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproGatifloxacin may increase the hypoglycemic activities of Insulin Lispro.Approved
IronThe serum concentration of Gatifloxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Gatifloxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Gatifloxacin can be decreased when it is combined with Iron saccharate.Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Gatifloxacin.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Gatifloxacin.Investigational
KebuzoneKebuzone may increase the neuroexcitatory activities of Gatifloxacin.Experimental
KetoprofenKetoprofen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Gatifloxacin.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Gatifloxacin.Experimental
Lanthanum carbonateThe serum concentration of Gatifloxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LeflunomideLeflunomide may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
LiraglutideGatifloxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisofyllineLisofylline may increase the neuroexcitatory activities of Gatifloxacin.Investigational
LonazolacLonazolac may increase the neuroexcitatory activities of Gatifloxacin.Experimental
LornoxicamLornoxicam may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Gatifloxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateThe serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium SulfateThe serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Gatifloxacin.Investigational
MecaserminGatifloxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Gatifloxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Gatifloxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Gatifloxacin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Gatifloxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Gatifloxacin.Approved, Vet Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Gatifloxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Gatifloxacin.Investigational, Withdrawn
MetforminGatifloxacin may increase the hypoglycemic activities of Metformin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Gatifloxacin.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Gatifloxacin.Experimental
MifepristoneGatifloxacin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolGatifloxacin may increase the hypoglycemic activities of Miglitol.Approved
MizoribineMizoribine may increase the neuroexcitatory activities of Gatifloxacin.Investigational
MofebutazoneMofebutazone may increase the neuroexcitatory activities of Gatifloxacin.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Gatifloxacin.Approved, Vet Approved
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Gatifloxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Gatifloxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Gatifloxacin.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Vet Approved
NateglinideGatifloxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Gatifloxacin.Investigational
NepafenacNepafenac may increase the neuroexcitatory activities of Gatifloxacin.Approved
NifenazoneNifenazone may increase the neuroexcitatory activities of Gatifloxacin.Experimental
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Gatifloxacin.Approved
NimesulideNimesulide may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Gatifloxacin.Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Gatifloxacin.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Gatifloxacin.Investigational
OlopatadineOlopatadine may increase the neuroexcitatory activities of Gatifloxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Gatifloxacin.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Gatifloxacin.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Gatifloxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Gatifloxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Gatifloxacin.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gatifloxacin.Approved, Vet Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Gatifloxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Gatifloxacin.Approved
ParthenolideParthenolide may increase the neuroexcitatory activities of Gatifloxacin.Investigational
PentamidineGatifloxacin may increase the hypoglycemic activities of Pentamidine.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Gatifloxacin.Experimental
PhenindioneGatifloxacin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonGatifloxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Gatifloxacin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Gatifloxacin.Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
PioglitazoneGatifloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
PirprofenPirprofen may increase the neuroexcitatory activities of Gatifloxacin.Experimental
PramlintideGatifloxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PranoprofenPranoprofen may increase the neuroexcitatory activities of Gatifloxacin.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Gatifloxacin.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Gatifloxacin.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Gatifloxacin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Gatifloxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Gatifloxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Gatifloxacin.Experimental, Investigational
ProbenecidThe serum concentration of Gatifloxacin can be increased when it is combined with Probenecid.Approved
ProglumetacinProglumetacin may increase the neuroexcitatory activities of Gatifloxacin.Experimental
PropacetamolPropacetamol may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
PropyphenazonePropyphenazone may increase the neuroexcitatory activities of Gatifloxacin.Experimental
ProquazoneProquazone may increase the neuroexcitatory activities of Gatifloxacin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Gatifloxacin.Experimental
PTC299PTC299 may increase the neuroexcitatory activities of Gatifloxacin.Investigational
QuinaprilThe serum concentration of Gatifloxacin can be decreased when it is combined with Quinapril.Approved, Investigational
QuinineGatifloxacin may increase the hypoglycemic activities of Quinine.Approved
RepaglinideGatifloxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Gatifloxacin.Approved, Experimental, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Ribociclib is combined with Gatifloxacin.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Gatifloxacin.Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Gatifloxacin.Investigational, Withdrawn
RosiglitazoneGatifloxacin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SalicylamideSalicylamide may increase the neuroexcitatory activities of Gatifloxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Gatifloxacin.Approved, Vet Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Gatifloxacin.Approved
SaxagliptinGatifloxacin may increase the hypoglycemic activities of Saxagliptin.Approved
SemapimodSemapimod may increase the neuroexcitatory activities of Gatifloxacin.Investigational
SeratrodastSeratrodast may increase the neuroexcitatory activities of Gatifloxacin.Approved
SerrapeptaseSerrapeptase may increase the neuroexcitatory activities of Gatifloxacin.Investigational
SevelamerSevelamer can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SitagliptinGatifloxacin may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SRT501SRT501 may increase the neuroexcitatory activities of Gatifloxacin.Investigational
Strontium ranelateThe serum concentration of Gatifloxacin can be decreased when it is combined with Strontium ranelate.Approved
SucralfateThe serum concentration of Gatifloxacin can be decreased when it is combined with Sucralfate.Approved
SulfadiazineGatifloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleGatifloxacin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Gatifloxacin.Approved
SulfisoxazoleGatifloxacin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Gatifloxacin.Approved
SunitinibGatifloxacin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the neuroexcitatory activities of Gatifloxacin.Experimental
TarenflurbilTarenflurbil may increase the neuroexcitatory activities of Gatifloxacin.Investigational
TenidapTenidap may increase the neuroexcitatory activities of Gatifloxacin.Experimental
TenoxicamTenoxicam may increase the neuroexcitatory activities of Gatifloxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Gatifloxacin.Vet Approved
TeriflunomideTeriflunomide may increase the neuroexcitatory activities of Gatifloxacin.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Gatifloxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Gatifloxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Gatifloxacin.Investigational
TioclomarolGatifloxacin may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Gatifloxacin.Approved
TolazamideGatifloxacin may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideGatifloxacin may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Gatifloxacin.Approved
TolmetinTolmetin may increase the neuroexcitatory activities of Gatifloxacin.Approved
TranilastTranilast may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Gatifloxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Gatifloxacin.Approved, Vet Approved
TribenosideTribenoside may increase the neuroexcitatory activities of Gatifloxacin.Experimental
TriptolideTriptolide may increase the neuroexcitatory activities of Gatifloxacin.Investigational
TromethamineTromethamine can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Gatifloxacin.Approved
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Gatifloxacin.Investigational, Withdrawn
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Gatifloxacin.Approved, Investigational
WarfarinGatifloxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
ZileutonZileuton may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the neuroexcitatory activities of Gatifloxacin.Withdrawn
Food Interactions
  • Absorption does not seem to be affected by milk or calcium carbonate, however, gatifloxacin bioavailability appears significantly reduced when combined with Ensure™ (Cmax is reduced by about 50% while total drug exposure (AUC) is reduced by about 25%).
  • Drink liberally.
  • Take without regard to meals.

References

Synthesis Reference
US4980470
General References
  1. Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, Dresser L, Low DE, Mamdani MM: Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med. 2006 Mar 30;354(13):1352-61. Epub 2006 Mar 1. [PubMed:16510739]
  2. Gurwitz JH: Serious adverse drug effects--seeing the trees through the forest. N Engl J Med. 2006 Mar 30;354(13):1413-5. Epub 2006 Mar 1. [PubMed:16510740]
External Links
Human Metabolome Database
HMDB15178
KEGG Drug
D08011
KEGG Compound
C07661
PubChem Compound
5379
PubChem Substance
46506159
ChemSpider
5186
BindingDB
50117914
ChEBI
5280
ChEMBL
CHEMBL31
Therapeutic Targets Database
DAP001387
PharmGKB
PA449738
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Gatifloxacin
ATC Codes
S01AE06 — GatifloxacinJ01MA16 — Gatifloxacin
AHFS Codes
  • 52:04.04 — Antibacterials
  • 08:12.18 — Quinolones
FDA label
Download (134 KB)
MSDS
Download (57.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
1CompletedScreeningCataract Extraction1
1CompletedScreeningHealthy Volunteers1
1, 2CompletedTreatmentTB Multi-drug Resistant1
2CompletedTreatmentAcute Bacterial Corneal Ulcers / Bacterial Keratitis1
2CompletedTreatmentConjunctivitis, Bacterial1
2TerminatedTreatmentUlcerative keratitis1
3CompletedTreatmentInfection and Inflammation After Refractive Surgery (Lasik)1
3RecruitingTreatmentKeratitis; Infectious Disease (Manifestation)1
3TerminatedTreatmentConjunctivitis, Bacterial1
4CompletedNot AvailableCataract operation1
4CompletedNot AvailableMacula Thickening1
4CompletedBasic ScienceAnti-Biotic Resistance1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedOtherInjections / Intravitreous1
4CompletedPreventionOphthalmic Surgery1
4CompletedTreatmentConjunctivitis, Bacterial1
4CompletedTreatmentSalmonella Typhi Infection1
4Unknown StatusPreventionEye Infections / Infection NOS1
Not AvailableCompletedNot AvailableCorneal Epithelial Wound Healing1
Not AvailableCompletedTreatmentEpithelium, Corneal1
Not AvailableSuspendedPreventionEndophthalmitis1
Not AvailableWithdrawnPreventionConjunctical Flora1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral200 mg
TabletOral400 mg
LiquidIntravenous10 mg
SolutionIntravenous2 mg
SolutionOphthalmic0.3 %
Solution / dropsOphthalmic5 mg/mL
Prices
Unit descriptionCostUnit
Zymar 0.3% Solution 5ml Bottle87.53USD bottle
Zymar 0.3% eye drops16.75USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4980470No1992-12-152009-12-15Us
CA2307632No2007-05-222019-08-20Canada
CA1340316No1999-01-122016-01-12Canada
US6333045Yes2000-02-202020-02-20Us
US5880283Yes1996-06-052016-06-05Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)182-185 °CNot Available
water solubility60 mg/mL (at pH 4)Not Available
logP2.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.631 mg/mLALOGPS
logP-0.23ALOGPS
logP-0.58ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)5.69ChemAxon
pKa (Strongest Basic)8.73ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area82.11 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity98.82 m3·mol-1ChemAxon
Polarizability38.29 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9279
Blood Brain Barrier-0.9869
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.9116
P-glycoprotein inhibitor INon-inhibitor0.7838
P-glycoprotein inhibitor IINon-inhibitor0.6997
Renal organic cation transporterNon-inhibitor0.804
CYP450 2C9 substrateNon-substrate0.8257
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6231
CYP450 1A2 substrateNon-inhibitor0.8535
CYP450 2C9 inhibitorNon-inhibitor0.8479
CYP450 2D6 inhibitorNon-inhibitor0.9124
CYP450 2C19 inhibitorNon-inhibitor0.8598
CYP450 3A4 inhibitorNon-inhibitor0.8804
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7502
Ames testAMES toxic0.605
CarcinogenicityNon-carcinogens0.8678
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3029 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8994
hERG inhibition (predictor II)Non-inhibitor0.7207
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - DI-ESI-qTof , NegativeLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-0169000000-7839341ea49cae9ec8cd
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0922000000-8e80b2969083df9af733
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-0279000000-0ee0061b508877e5251c
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00kr-0942000000-432aa78e495cb764bf6a

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
N-arylpiperazines / Fluoroquinolones / Aminoquinolines and derivatives / Hydroquinolones / Haloquinolines / Hydroquinolines / Pyridinecarboxylic acids / Methoxyanilines / Anisoles / Dialkylarylamines
show 13 more
Substituents
Quinoline-3-carboxylic acid / Fluoroquinolone / N-arylpiperazine / Aminoquinoline / Haloquinoline / Dihydroquinolone / Dihydroquinoline / Pyridine carboxylic acid or derivatives / Pyridine carboxylic acid / Methoxyaniline
show 33 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organofluorine compound, N-arylpiperazine, quinolone antibiotic, quinolone, quinolinemonocarboxylic acid (CHEBI:5280)

Targets

Kind
Protein
Organism
Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, inc...
Gene Name
gyrA
Uniprot ID
P72524
Uniprot Name
DNA gyrase subunit A
Molecular Weight
92052.595 Da
References
  1. Harding I, Simpson I: Fluoroquinolones: is there a different mechanism of action and resistance against Streptococcus pneumoniae? J Chemother. 2000 Oct;12 Suppl 4:7-15. [PubMed:11131958]
  2. Rafii F, Park M, Novak JS: Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones. Antimicrob Agents Chemother. 2005 Feb;49(2):488-92. [PubMed:15673722]
  3. Kays MB, Zhanel GG, Reimann MA, Jacobi J, Denys GA, Smith DW, Wack MF: Selection of a gyrA mutation and treatment failure with gatifloxacin in a patient with Streptococcus pneumoniae with a preexisting parC mutation. Pharmacotherapy. 2007 Feb;27(2):221-6. [PubMed:17253913]
  4. Kim OK, Ohemeng K, Barrett JF: Advances in DNA gyrase inhibitors. Expert Opin Investig Drugs. 2001 Feb;10(2):199-212. [PubMed:11178337]
  5. Hosaka M: [Antibacterial property and clinical effect of gatifloxacin, a novel quinolone antibacterial agent]. Nihon Yakurigaku Zasshi. 2003 Jun;121(6):447-56. [PubMed:12835539]
  6. Mdluli K, Ma Z: Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets. 2007 Jun;7(2):159-68. [PubMed:17970226]
Kind
Protein
Organism
Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Magnesium ion binding
Specific Function
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, inc...
Gene Name
gyrB
Uniprot ID
P0A4L9
Uniprot Name
DNA gyrase subunit B
Molecular Weight
72237.025 Da
References
  1. Harding I, Simpson I: Fluoroquinolones: is there a different mechanism of action and resistance against Streptococcus pneumoniae? J Chemother. 2000 Oct;12 Suppl 4:7-15. [PubMed:11131958]
  2. Rafii F, Park M, Novak JS: Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones. Antimicrob Agents Chemother. 2005 Feb;49(2):488-92. [PubMed:15673722]
  3. Kays MB, Zhanel GG, Reimann MA, Jacobi J, Denys GA, Smith DW, Wack MF: Selection of a gyrA mutation and treatment failure with gatifloxacin in a patient with Streptococcus pneumoniae with a preexisting parC mutation. Pharmacotherapy. 2007 Feb;27(2):221-6. [PubMed:17253913]
  4. Kim OK, Ohemeng K, Barrett JF: Advances in DNA gyrase inhibitors. Expert Opin Investig Drugs. 2001 Feb;10(2):199-212. [PubMed:11178337]
  5. Hosaka M: [Antibacterial property and clinical effect of gatifloxacin, a novel quinolone antibacterial agent]. Nihon Yakurigaku Zasshi. 2003 Jun;121(6):447-56. [PubMed:12835539]
  6. Mdluli K, Ma Z: Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets. 2007 Jun;7(2):159-68. [PubMed:17970226]
Kind
Protein
Organism
Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name
parC
Uniprot ID
P72525
Uniprot Name
DNA topoisomerase 4 subunit A
Molecular Weight
93132.2 Da
References
  1. Harding I, Simpson I: Fluoroquinolones: is there a different mechanism of action and resistance against Streptococcus pneumoniae? J Chemother. 2000 Oct;12 Suppl 4:7-15. [PubMed:11131958]
  2. Rafii F, Park M, Novak JS: Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones. Antimicrob Agents Chemother. 2005 Feb;49(2):488-92. [PubMed:15673722]
  3. Kays MB, Zhanel GG, Reimann MA, Jacobi J, Denys GA, Smith DW, Wack MF: Selection of a gyrA mutation and treatment failure with gatifloxacin in a patient with Streptococcus pneumoniae with a preexisting parC mutation. Pharmacotherapy. 2007 Feb;27(2):221-6. [PubMed:17253913]
  4. Hosaka M: [Antibacterial property and clinical effect of gatifloxacin, a novel quinolone antibacterial agent]. Nihon Yakurigaku Zasshi. 2003 Jun;121(6):447-56. [PubMed:12835539]
  5. Mdluli K, Ma Z: Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets. 2007 Jun;7(2):159-68. [PubMed:17970226]
Kind
Protein
Organism
Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Magnesium ion binding
Specific Function
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name
parE
Uniprot ID
Q59961
Uniprot Name
DNA topoisomerase 4 subunit B
Molecular Weight
71663.86 Da
References
  1. Harding I, Simpson I: Fluoroquinolones: is there a different mechanism of action and resistance against Streptococcus pneumoniae? J Chemother. 2000 Oct;12 Suppl 4:7-15. [PubMed:11131958]
  2. Rafii F, Park M, Novak JS: Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones. Antimicrob Agents Chemother. 2005 Feb;49(2):488-92. [PubMed:15673722]
  3. Kays MB, Zhanel GG, Reimann MA, Jacobi J, Denys GA, Smith DW, Wack MF: Selection of a gyrA mutation and treatment failure with gatifloxacin in a patient with Streptococcus pneumoniae with a preexisting parC mutation. Pharmacotherapy. 2007 Feb;27(2):221-6. [PubMed:17253913]
  4. Hosaka M: [Antibacterial property and clinical effect of gatifloxacin, a novel quinolone antibacterial agent]. Nihon Yakurigaku Zasshi. 2003 Jun;121(6):447-56. [PubMed:12835539]
  5. Mdluli K, Ma Z: Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets. 2007 Jun;7(2):159-68. [PubMed:17970226]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Guo M, Zou JW, Yi PG, Shang ZC, Hu GX, Yu QS: Binding interaction of gatifloxacin with bovine serum albumin. Anal Sci. 2004 Mar;20(3):465-70. [PubMed:15068289]
  2. Tan F, Guo M, Yu Q: Studies on interaction between gatifloxacin and human serum albumin as well as effect of copper(II) on the reaction. Spectrochim Acta A Mol Biomol Spectrosc. 2005 Oct;61(13-14):3006-12. Epub 2004 Dec 19. [PubMed:16165044]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:33